Myelin Basic Protein (MBP) (68

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Myelin Basic Protein (MBP) (68-82), guinea pig

CAS No. : 98474-59-0

MCE 国际站：Myelin Basic Protein (MBP) (68-82), guinea pig

产品活性：Myelin Basic Protein (MBP) (68-82), guinea pig 是髓鞘碱性蛋白 (MBP) 的一个片段。

研究领域：Others

作用靶点：Others

In Vitro: Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. In this study, whole blood samples are analyzed for activation capacity and the activatability of CD4⁺ and CD8⁺ T-lymphocytes by human total myelin basic protein (MBP), human MBP 104-118 fragment, and guinea pig MBP (68-82) fragment. A significant increase in the number of activated T-lymphocytes was observed in the whole blood. For all three tested MBPs, this increase in activated CD4⁺ and CD8⁺ T-lymphocytes is statistically significant (p<0.01). However, this increase in activated T-cells is most prominent following incubation with human total MBP, followed by human 104-118 fragment; the smallest increase is observed following incubation with guinea pig MBP (68-82) fragment (human total MBP>huMBP-104-118>guinea pig MBP (68-82)).

In Vivo: Whether pretreatment with bee venom acupuncture (BVA) from the same day of MBP (68-82) immunization can affect the induction and progression of experimental autoimmune encephalomyelitis (EAE) and weight loss is examined. At 5-9 days after immunization, rats in the myelin basic protein (MBP) group start displaying partial loss of tail tonus (clinical signs, 0.5) in a freely moving environment. At 10-16 days after immunization, most of the rats in the MBP group display more severe symptoms of neurological deficit including paraparesis of the hindlimb, paraplegia, tetraparesis, and tetraplegia. In contrast, rats in the MBP + BVA group display relatively slight neurological deficits in a dose-dependent manner at 11-15 days after immunization, compared to the rats in the MBP group. The onset of symptoms is slightly delayed (BVA 0.8 mg/kg, 6.4±0.6 days) and the maximal clinical score is markedly decreased (BVA 0.25 mg/kg, 3.7±0.2; BVA 0.8 mg/kg, 2.8±0.3), compared to that in the MBP group. At this time, the mean body weight of rats in the MBP group is decreased as compared to that of rats in the normal group, but it is significantly increased in rats of the MBP + BVA group as compared to rats in the MBP group.

相关产品：Bioactive Compound Library Plus  |  PEG300  |  SBE-β-CD  |  Corn oil  |  Tween 80  |  Polyethylene glycol 12-hydroxystearate  |  JC-1  |  DTT  |  CFSE  |  Digitonin  |  Lipopolysaccharides  |  Thiazolyl Blue  |  D-Luciferin potassium salt  |  (2-Hydroxypropyl)-β-cyclodextrin  |  Methyl-β-cyclodextrin  |  Biotin  |  Monocrotaline  |  Auxinole  |  Nile Red  |  3X FLAG peptide TFA  |  FLAG peptide  |  Tocofersolan  |  DAPI dihydrochloride  |  Propidium Iodide  |  Cremophor EL  |  Yoda 1  |  IPTG  |  Calcein-AM  |  GsMTx4 TFA

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。